IPHA Innate Pharma

USD 2.38 -0.06 -2.459016
Icon

Innate Pharma (IPHA) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 2.38

-0.06 (-2.46)%

USD 0.22B

5.21K

USD 11.50(+383.19%)

N/A

Icon

IPHA

Innate Pharma (USD)
COMMON STOCK | NSD
USD 2.38
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.22B

N/A

USD 2.38

Innate Pharma (IPHA) Stock Forecast

Show ratings and price targets of :
USD 11.50
(+383.19%)

Based on the Innate Pharma stock forecast from 1 analysts, the average analyst target price for Innate Pharma is USD 11.50 over the next 12 months. Innate Pharma’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Innate Pharma is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Innate Pharma’s stock price was USD 2.38. Innate Pharma’s stock price has changed by -4.80% over the past week, -11.43% over the past month and -21.71% over the last year.

No recent analyst target price found for Innate Pharma
No recent average analyst rating found for Innate Pharma

Company Overview Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and pe...Read More

117, Avenue de Luminy, Marseille, France, 13009

191

December

USD

USA

Adjusted Closing Price for Innate Pharma (IPHA)

Loading...

Unadjusted Closing Price for Innate Pharma (IPHA)

Loading...

Share Trading Volume for Innate Pharma Shares

Loading...

Compare Performance of Innate Pharma Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for IPHA

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Innate Pharma (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S -1.36 (-1.05%) USD554.45B 46.01 4.80

ETFs Containing IPHA

Symbol Name IPHA's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Innate Pharma (IPHA) Stock

Based on ratings from 1 analysts Innate Pharma's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.

Unfortunately we do not have enough data on IPHA's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for IPHA is USD 11.50 over the next 12 months. The maximum analyst target price is USD 11.5 while the minimum anlayst target price is USD 11.5.

IPHA stock's Price/Earning ratio is 13.66. Our analysis grades IPHA stock's Price / Earning ratio at F. This means that IPHA stock's Price/Earning ratio is above 64% of the stocks in the Biotechnology sector in the NSD exchange. Based on this IPHA may be a overvalued for its sector.

The last closing price of IPHA's stock was USD 2.38.

The most recent market capitalization for IPHA is USD 0.22B.

Based on targets from 1 analysts, the average taret price for IPHA is projected at USD 11.50 over the next 12 months. This means that IPHA's stock price may go up by +383.19% over the next 12 months.

We can't find any ETFs which contains Innate Pharma's stock.

As per our most recent records Innate Pharma has 191 Employees.

Innate Pharma's registered address is 117, Avenue de Luminy, Marseille, France, 13009. You can get more information about it from Innate Pharma's website at https://www.innate-pharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...